Clinical Trials on Chronic Lymphocytic Leukaemia

Total 36902 results

National Cancer Institute (NCI)

Terminated

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

T-cell Large Granular Lymphocyte Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | T-Cell Large Granular Lymphocyte Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage...

United States, Denmark, Italy
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Leukemia | CLL (Chronic Lymphocytic Leukemia) | Leukemia, Lymphocytyc | SLL (Small Lymphocytic Lymphoma)

United States
GlaxoSmithKline

Completed

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Korea, Republic of, Japan
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
GlaxoSmithKline

Completed

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Japan
GlaxoSmithKline
Genmab

Completed

Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

Leukaemia, Lymphocytic, Chronic

Sweden
Shanghai Zhongshan Hospital
Shanghai Changzheng Hospital

Recruiting

Selenious Yeast in CLL Patients w/o Indication of Chemotherapy

Chronic Lymphocytic Leukemia Stage A(0) | Chronic Lymphocytic Leukemia Stage A(I) | Chronic Lymphocytic Leukemia Stage A(II) | Chronic Lymphocytic Leukaemia Stage B(I)

China
GlaxoSmithKline

Completed

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

Leukaemia, Lymphocytic, Chronic
GlaxoSmithKline

Completed

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Leukaemia, Lymphocytic, Chronic

Australia, United States, New Zealand
GlaxoSmithKline

Completed

Phase IV Observational Study in Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic
Novartis Pharmaceuticals

Completed

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

India, United Kingdom, Netherlands, Canada, Germany, Greece, Italy, Poland, Russian Federation, Spain, Taiwan, Thailand, United States, Brazil, Bulgaria, Mexico, Romania, Ukraine
Novartis Pharmaceuticals

Terminated

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1)

Leukaemia, Lymphocytic, Chronic

Spain, United States, Belgium, India, United Kingdom, Netherlands, Czechia, Germany, Greece, Italy, Russian Federation, Sweden, Canada, Ireland, Poland, France, Brazil
Gilead Sciences

Completed

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

Chronic Lymphocytic Leukaemia

United Kingdom, Ireland
GlaxoSmithKline

Completed

Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients (BIFROST)

Leukaemia, Lymphocytic, Chronic

United States, United Kingdom
Novartis Pharmaceuticals

Terminated

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG)

Leukaemia, Lymphocytic, Chronic

Belgium, Netherlands, United States, Argentina, Czechia, Denmark, France, Greece, Israel, Russian Federation, Sweden, Korea, Republic of, Australia, Brazil, Canada, Italy, Spain, Turkey, Hungary, Finland, Poland, Ukraine, Puerto Rico, Indi... and more
University Health Network, Toronto
Celgene

Terminated

Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) (Rev-CLL)

Chronic Lymphocytic Leukaemia

Canada
University of Liverpool
GlaxoSmithKline; Chugai Pharma USA; Napp Pharmaceuticals Limited

Unknown

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (RIAltO)

Chronic Lymphocytic Leukaemia

United Kingdom
The Christie NHS Foundation Trust
Celgene Corporation; Leukemia Research Fund

Terminated

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial (RESPeCT)

Chronic Lymphocytic Leukaemia

United Kingdom
King's College Hospital NHS Trust

Completed

CLL Empirical Antibiotic Regimen (CLEAR)

Chronic Lymphocytic Leukaemia (CLL)

United Kingdom
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
European Institute of Oncology

Terminated

R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukaemia

Italy
Gruppo Italiano Studio Linfomi

Completed

Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders

Chronic Lymphocytic Leukaemia

Italy
Royal Marsden NHS Foundation Trust

Completed

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Chronic Lymphocytic Leukaemia
AstraZeneca

Recruiting

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Japan
AstraZeneca

Recruiting

Retention Rate of Acalabrutinib in a Non-interventional Setting (RETAIN)

Chronic Lymphocytic Leukaemia (CLL)

Germany
Novartis Pharmaceuticals

Completed

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Leukaemia

Belgium, Austria, Czechia, France, Germany, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Ireland, Italy, Slovakia, Bulgaria, Singapore, Ukraine, Poland
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Chronic Lymphocytic Leukaemia | Non Hodgkins Lymphoma

United Kingdom, France
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust; University Hospital Plymouth...

Unknown

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib (CLARITY)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukaemia

United Kingdom
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia (LLC1114)

Adult Patients | Chronic Lymphocyte Leukemia

Italy
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
National Cancer Institute (NCI)

Terminated

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
CABYC
Bayer; Genzyme, a Sanofi Company; Fundacion Clinic per a la Recerca Biomédica; Grupo... and other collaborators

Withdrawn

R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia (R-CHOP)

Chronic Lymphocytic Leukaemia | Patients Resistant to a Purine Analogous | Patients Relapsed With Purines Therapy

Spain
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
GlaxoSmithKline

Completed

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphoblastic

Japan
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Study on the Diagnosis and Management of CLL in Italy by GIMEMA

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type

Italy
Roswell Park Cancer Institute

Withdrawn

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
Astellas Pharma International B.V.

Terminated

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) (NADIR)

Chronic Lymphocytic Leukaemia (CLL) | Indolent Non Hodgkin's Lymphoma (iNHL)

Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
Roswell Park Cancer Institute
National Cancer Institute (NCI); Celgene Corporation

Terminated

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Terminated

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

B-cell Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Contiguous Stage II Small Lymphocytic Lymphoma | Noncontiguous Stage II Small Lymphocytic Lymphoma | Stage... and other conditions

United States
Fred Hutchinson Cancer Research Center/University...

Withdrawn

Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)

Terminated

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States

Clinical Trials on Chronic Lymphocytic Leukaemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations